St. Jude Tracking of Viral and Host Factors Associated With COVID-19

COVID-19 Clinical Trial

Official title:

SJTRC-St. Jude Tracking of Viral and Host Factors Associated With COVID-19: A Prospective Adaptive Cohort Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04362995
• Other study ID #: SJTRC
• Secondary ID: NIH1P01AI165077-
• Status: Active, not recruiting
• Start date: April 23, 2020
• Est. completion date: March 2027

Study information

• Verified date: April 2024
• Source: St. Jude Children's Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective adaptive cohort study of St. Jude employees to determine the rate of SARS-CoV-2 infections that are asymptomatic and to evaluate immunological responses to SARS-CoV-2 infection. Primary Objectives - To estimate the proportion of asymptomatic infection with SARS-CoV-2 infection in a population of SARS-CoV-2-naïve adult St. Jude employees - To comprehensively map CD4 and CD8 T cell epitopes and response magnitudes to SARS-CoV-2 infection in a population of SARS-CoV-2-naïve adult St. Jude employees who acquire SARS-CoV-2 infection - To measure changes in the CD4 and CD8 response magnitude and function to SARS-CoV-2 infection and/or vaccination in a population of St. Jude employees for up to 48 months after infection and/or vaccination. Secondary Objectives - To establish seroprevalence of SARS-CoV-2-specific antibodies at baseline, and identify the rate of seroconversion to SARS-CoV-2 in a population of presumably naïve adult St. Jude employees - To identify features of T cell responses at baseline and during SARS-CoV-2 infection that are associated with protection against symptomatic or severe COVID-19 disease in a population of adult St. Jude employees - To identify risk factors for long-term protection against COVID-19 in a population of adult St. Jude employees - To evaluate changes in antibody responses to SARS-CoV-2 in a population of St. Jude employees for up to 48 months after SARS-CoV-2 infection and/or vaccination. - To evaluate the saliva antibody and cytokine response to SARS-CoV-2 infection and/or vaccination and identify characteristics that predict protection from subsequent SARS-CoV-2 infection among a population of St. Jude employees followed for up to 48 months after SARS-CoV-2 infection and/or vaccination. - To measure changes in saliva antibody responses to SARS-CoV-2 for up to 48 months after SARS-CoV-2 infection and/or vaccination. Exploratory Objectives - To establish additional immunological features including host immune or receptor polymorphisms associated with response to SARS-CoV-2 infection - To explore SARS-CoV-2 diversity and specific features in a circumscribed population - To describe the presence, characteristics, and proportion of short-term re-infection - To determine if an association between SARS-CoV-2 viral load in nasal swab specimens and COVID-19 symptoms can be identified in a population of adult St. Jude employees who acquire SARS-CoV-2 - To explore the laboratory and clinical response to SARS-CoV-2 vaccine in a population of adult St. Jude employees with and without a history of SARS-CoV-2 infection

Description:

Naive individuals will contribute a baseline blood sample at enrollment. Subsequent routine blood draws will occur to determine the proportion of participants who have asymptomatically seroconverted; the timing of these blood draws and proportion of participants required will be determined by the rate of documented SARS-CoV-2 infection in the cohort according to an adaptive study design. Participants will be tracked for SARS-CoV-2 specific antibodies and CD4, and CD8 T cell responses throughout the period and especially during the early stages after clearance of infection and subsequently to determine the quality and duration of memory responses. In addition to blood samples, participants will intermittently provide nasal swabs for detection of SARS-CoV-2; this will occur either through a comprehensive proactive employee screening program, or specifically for the purposes of the research study if participants are required to attend campus but are not currently eligible for employee screening. These will determine duration and characteristics of viral shedding and identify reinfection. Seroprevalence estimates and asymptomatic conversion will also be determined. Individuals with a diagnosis of COVID-19 infection will have two additional blood draws in the acute and convalescent phase to identify acute and late immune responses. These responses will be compared to the essential baseline sample data to characterize the generation of de novo and cross-reactive recall responses. For those participants receiving vaccination, blood draws will be taken after COVID vaccine (3-8 weeks after completion of 1 or 2 dose course) and at completion of study. At enrollment, subjects will complete a baseline online personal health and demographic questionnaire, and then monthly brief online health update questionnaires. Throughout the study period, subjects will complete a brief online symptom survey every 2 weeks. Participants in the original SJTRC study will be asked to reconsent to complete a one-time questionnaire regarding their COVID-19 experience specifically during the time since they went off study. Once this questionnaire is complete, they will be taken off study and receive no further questionnaires related to the original study. A subset of participants will be invited to re-enroll in a long-term follow-up phase to evaluate long-term immunity and protection against COVID-19 following infection and vaccination. Participants will provide blood samples every 6 months. They will also be invited to provide additional acute and convalescent samples (blood and saliva), if diagnosed with acute COVID-19 during this period. Participants will continue to complete regular questionnaires, but the frequency will decrease to 6 monthly (health questionnaires) and as needed (COVID-19 diagnosis or vaccination).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1316
• Est. completion date: March 2027
• Est. primary completion date: April 2025
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adult St. Jude employees (Age = 18 years of age) who are presumed to be SARS- CoV-2 naive, or have a recent diagnosis of COVID-19, and volunteer to participate.

2. Willing to undergo blood draws on up to 5 occasions during the study.

3. Receiving approximately twice-weekly SARS-CoV-2 screening by Occupational Health, or willing to provide up to twice weekly nasal self-swabs if attending campus.

4. Have access to a personal smartphone that is able to receive and respond to text messages for data collection.

5. Has ready access to the internet to log personal study information into the REDCap database.

6. Self-identified as able to speak and read English well enough to understand the consent process and survey forms, and to report symptoms.

Inclusion Criteria for LTFU arm:

1. Adult St. Jude employees (age = 18 years of age) who participated in the original SJTRC study.

2. Willing to undergo blood draws on up to five occasions during the LTFU arm. Willing to provide saliva samples at acute and convalescent episodes.

3. Have access to a personal smartphone that is able to receive and respond to text messages for data collection.

4. Have ready access to the internet to log personal study information into the REDCap database.

5. Self-identified as able to speak and read English well enough to understand the consent process and questionnaires, and to report symptoms.

Exclusion Criteria:

1. Employees who are first-degree relatives of, or directly or indirectly report up to, the PI or any of the clinical study investigators who will have access to participant identities.

2. Employees who cannot complete the informed consent process.

Exclusion Criteria for LTFU arm:

1. Employees who did not participate in the original SJTRC study.

2. Employees who cannot complete the informed consent process.

Related Conditions & MeSH terms

• Coronavirus
• Coronavirus Infection
• Coronavirus Infections
• COVID-19
• SARS-CoV-2

Locations

Country	Name	City	State
United States	St. Jude Children's Research Hospital	Memphis	Tennessee

Sponsors (4)

Lead Sponsor	Collaborator
St. Jude Children's Research Hospital	National Institute of Allergy and Infectious Diseases (NIAID), University of Georgia, University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of asymptomatic subjects	The proportion of participants who test positive for SARS-CoV-2 infection but remain asymptomatic.	1 year from enrollment
Primary	Positive CD4 and CD8 cell epitope positive response	A list of CD4 and CD8 cell epitopes with a magnitude change from baseline that is at least twice the standard deviation of the baseline.	at enrollment, 3 months, 6 months, 9 months and 1 year
Primary	Positive CD4 and CD8 cell epitope positive response	A list of CD4 and CD8 cell epitopes with a magnitude change from baseline that is at least twice the standard deviation of the baseline.	up to 48 months of additional observation in participants who have had COVID-19 or vaccination
Secondary	Proportion of seroprevalence	The proportion of participants at each time point who have detectable antibodies that recognize SARS-COV-2.	Baseline, 3 months, 6 months, 9 months and 1 year
Secondary	T-cell response	For CD8s, T cell responses will be categorized as cytolytic, cytokine producing, or exhausted. For CD4s they will be grouped as Th1, Th2, Tfh, or Th17. Percentages of cells in each category will be summarized at baseline and during SARS-CoV-2 infection.	Baseline, 3 months, 6 months, 9months, 1 year and 6 monthly for an additional 48 months in participants included in the long-term follow-up arm
Secondary	Protective antibody responses against SARS-CoV-2 at last follow-up sample	For participants who have enrolled in the long-term follow-up arm of the study, associations between persistent protective antibody responses and clinical and laboratory characteristics will be evaluated by paired tests and regression models.	up to 48 months of additional observation in participants who have had COVID-19 or vaccination
Secondary	Change in antibody responses to SARS-CoV-2	For participants who have enrolled in the long-term follow-up arm of the study, changes in antibody levels from baseline in paired samples.	up to 48 months of additional observation in participants who have had COVID-19 or vaccination
Secondary	Saliva antibody and cytokine responses to SARS-CoV-2	For participants who have enrolled in the long-term follow-up arm of the study, changes in saliva antibody and cytokine levels from baseline.	up to 48 months of additional observation in participants who have had COVID-19 or vaccination

External Links

•   ClinicalTrials Open at St. Jude
•   St. Jude Children's Research Hospital